Rob Coker

1 week ago | themedicinemaker.com | Rob Coker

As US president Donald Trump continues to impose his various agendas, we summarize the latest news and how it affects the manufacturing, distribution, and consumption of pharmaceuticals. Trump has initiated Section 232 investigations into pharmaceutical and semiconductor imports, citing national security concerns over US reliance on foreign production. Announced on April 14, analysts are preparing for 10-25 percent tariffs by mid-May.

1 week ago | themedicinemaker.com | Rob Coker

Antibody-drug conjugates (ADCs) have long since promised to become the smart weapon of oncology by combining the specificity of antibodies with the potency of small molecule drugs. After decades of slow and steady progress, is the field finally hitting the accelerator? New advances in drug-to-antibody ratio (DAR), multispecific targeting, and nontraditional payloads could rewrite the ADC playbook, while simultaneously surfacing new scientific, manufacturing, and commercial challenges.

2 weeks ago | themedicinemaker.com | Rob Coker

An international team of scientists has discovered new hidden pathways on the surface of cells that could change how drugs work in the body – and open the door to more precise and effective treatments for a wide range of diseases. The discovery centers on special proteins called G protein-coupled receptors (GPCRs), which sit on the surface of cells and detect external molecules to activate an appropriate response.

2 weeks ago | themedicinemaker.com | Rob Coker

The US Food and Drug Administration (FDA) has announced its intention to phase out mandatory animal testing for monoclonal antibodies and other drugs with the aim of modernizing preclinical translational science, enhancing drug safety, reducing development costs, and expediting the approval process by adopting advanced, human-relevant testing methodologies.​ The FDA's new strategy centers on the implementation of New Approach Methodologies (NAMs), which encompass AI-based models,...

2 weeks ago | themedicinemaker.com | Rob Coker

Look out for the 2025 Power List on April 28!Whether you’re a bench scientist, a biotech founder, or someone passionate about the future of healthcare, the 2025 Power List offers plenty of reasons to be inspired. While you wait for the 2025 list, why not remind yourself of 2024’s big hitters.